Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
Relapsed / Refractory AMLRelapsed / Refractory MDS
Interventions
DRUG

BYON4413

BYON4413 will be administered by IV infusion.

Trial Locations (9)

Unknown

RECRUITING

Het Ziekenhuisnetwerk Antwerpen, Antwerp

RECRUITING

UZ Leuven, Leuven

RECRUITING

Universitair Medisch Centrum Groningen, Groningen

RECRUITING

Institut Catala d'Oncologia, Badalona

RECRUITING

Hospital Clinic de Barcelona, Barcelona

RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona

RECRUITING

Hospital San Pedro de Alcantara, Cáceres

RECRUITING

Hospital Universitario de Salamanca, Salamanca

RECRUITING

Hospital Universitario y Politecnico La Fe, Valencia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Byondis B.V.

INDUSTRY